Randomized trial identifies proteomic biomarkers in myelodysplastic syndromes, suggesting improved diagnosis and prognosis.
Key Points
The study aims to explore the potential of proteomics for identifying novel biomarkers in myelodysplastic syndromes that can enhance diagnosis and prognosis.
Comprehensive proteomic analysis of hematopoietic disorders with a focus on myelodysplastic syndromes.
Identification of dysregulated proteins involved in signaling pathways, immune responses, and metabolic changes.
Validation of candidate biomarkers in clinical cohorts to assess their utility in practice.
Several candidate biomarkers linked to poor outcomes and immune evasion, including CAMK1D and IGF2BP3.
Proteins associated with chemoresistance and disease progression identified, impacting patient management.
Metabolic enzymes such as LDHA correlate with aggressive disease biology, underscoring the need for tailored therapies.